Advanced search
Publication Cover
Pharmaceutical Biology Volume 49, 2011 - Issue 6
Submit an article Journal homepage
887
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli

Xue-Gang Luo
,
Wen-Jing Tian
,
Meng NiCollege of Bioengineering, Tianjin University of Science and Technology, Tianjin
,
Xiao-Lan JingCollege of Bioengineering, Tianjin University of Science and Technology, Tianjin
,
Li-Hui LvCollege of Bioengineering, Tianjin University of Science and Technology, Tianjin
,
Nan WangCollege of Bioengineering, Tianjin University of Science and Technology, Tianjin
,
Yong JiangCollege of Bioengineering, Tianjin University of Science and Technology, Tianjin
&
Tong-Cun ZhangCorrespondence[email protected] [email protected]
 show all
Pages 653-657 | Received 12 Sep 2010, Accepted 10 Oct 2010, Published online: 09 May 2011

References

  • Adams HP Jr. (2003). Stroke: A vascular pathology with inadequate management. J Hypertens Suppl, 21, S3–S7.
  • Baker WF Jr. (2005). Thrombolytic therapy: Current clinical practice. Hematol Oncol Clin North Am, 19, 147–81, vii.
  • Gang J, Jiang CY, Du LX, Lu FP, Guo HJ, Li D, Liu HY. (2006). Cloning of reteplase gene and expression of the gene in Pichia methanolica. J South China Univ of Technol (Natural Science Edition) 12: 25–50.
  • Goldstone D, Haebel PW, Katzen F, Bader MW, Bardwell JC, Beckwith J, Metcalf P. (2001). DsbC activation by the N-terminal domain of DsbD. Proc Natl Acad Sci USA, 98, 9551–9556.
  • Inaba K. (2008). Protein disulfide bond generation in Escherichia coli DsbB-DsbA. J Synchrotron Radiat, 15, 199–201.
  • Inaba K. (2009). Disulfide bond formation system in Escherichia coli. J Biochem, 146, 591–597.
  • Ito K, Inaba K. (2008). The disulfide bond formation (Dsb) system. Curr Opin Struct Biol, 18, 450–458.
  • Kalyan NK, Lee SG, Wilhelm J, Fu KP, Hum WT, Rappaport R, Hartzell RW, Urbano C, Hung PP. (1988). Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem, 263, 3971–3978.
  • Ke H, Zhang S, Li J, Howlett GJ, Wang CC. (2006). Folding of Escherichia coli DsbC: Characterization of a monomeric folding intermediate. Biochemistry, 45, 15100–15110.
  • Larsen GR, Metzger M, Henson K, Blue Y, Horgan P. (1989). Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood, 73, 1842–1850.
  • Liu X, Wang CC. (2001). Disulfide-dependent folding and export of Escherichia coli DsbC. J Biol Chem, 276, 1146–1151.
  • Manosroi J, Tayapiwatana C, Götz F, Werner RG, Manosroi A. (2001). Secretion of active recombinant human tissue plasminogen activator derivatives in Escherichia coli. Appl Environ Microbiol, 67, 2657–2664.
  • Messens J, Collet JF. (2006). Pathways of disulfide bond formation in Escherichia coli. Int J Biochem Cell Biol, 38, 1050–1062.
  • Missiakas D, Schwager F, Raina S. (1995). Identification and characterization of a new disulfide isomerase-like protein (DsbD) in Escherichia coli. Embo J, 14, 3415–3424.
  • Nakamoto H, Bardwell JC. (2004). Catalysis of disulfide bond formation and isomerization in the Escherichia coli periplasm. Biochim Biophys Acta, 1694, 111–119.
  • Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. (1983). Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature, 301, 214–221.
  • Qiu J, Swartz JR, Georgiou G. (1998). Expression of active human tissue-type plasminogen activator in Escherichia coli. Appl Environ Microbiol, 64, 4891–4896.
  • Qureshi AI, Pande RU, Kim SH, Hanel RA, Kirmani JF, Yahia AM. (2002). Third generation thrombolytics for the treatment of ischemic stroke. Curr Opin Investig Drugs, 3, 1729–1732.
  • Renatus M, Bode W, Huber R, Stürzebecher J, Prasa D, Fischer S, Kohnert U, Stubbs MT. (1997). Structural mapping of the active site specificity determinants of human tissue-type plasminogen activator. Implications for the design of low molecular weight substrates and inhibitors. J Biol Chem, 272, 21713–21719.
  • Simpson D, Siddiqui MA, Scott LJ, Hilleman DE. (2006). Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs, 6, 265–285.
  • van Zonneveld AJ, Veerman H, Pannekoek H. (1986). Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci USA, 83, 4670–4674.
  • Wooster MB, Luzier AB. (1999). Reteplase: A new thrombolytic for the treatment of acute myocardial infarction. Ann Pharmacother, 33, 318–324.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.